FCX vs LUNG · P/E 38, rev $25.45B vs rev $83.8M
Freeport-McMoran Copper & Gold Inc (FCX) versus Pulmonx Corp (LUNG) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Pulmonx Corp (LUNG) is a medical devices company listed on US.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported LUNG revenue for 2024-12-31 was $83.8M. Net income was -$56.4M. Revenue was up 22.0% from 2023-12-31 to 2024-12-31. LUNG currently screens at market cap $111.9M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. LUNG currently screens at market cap $111.9M.
Not investment advice. Open the FCX and LUNG stock pages for the full models.
Not investment advice.